Licochalcone a: A promising antiparasitic drug against giardiasis
- PMID: 39693890
- PMCID: PMC11720111
- DOI: 10.1016/j.ijpddr.2024.100573
Licochalcone a: A promising antiparasitic drug against giardiasis
Abstract
Giardiasis, caused by Giardia duodenalis, is a prevalent and significant zoonotic disease. While nitroimidazole drugs are primarily used to treat giardiasis, the urgent need for the development and formulation of new drugs has arisen due to increasing drug resistance. Several plant derived medicine have been employed as antiparasitic drugs. This study has evaluated the anti-Giardia effect of Licochalcone A (Lic A) through both in vitro and in vivo experiments. We determined the 50% inhibitory concentration (IC50) of Lic A, analyzed the adhesive ability of G. duodenalis, and assessed intestinal morphology and various indicators in the gerbil model. The in vitro assays demonstrated that the IC50 value of Lic A against G. duodenalis was 27.42 μM. Additionally, Lic A significantly inhibited the adhesiveability of G. duodenalis trophozoites, impairing their cell structure and cytoskeleton. In vivo experiments showed that Lic A significantly mitigated weight loss due to G. duodenalis infection, and lowered the intestinal parasite load. Histopathological examinations in gerbils indicated that Lic A could reduce intestinal damage, increase the height of intestinal villi, decrease crypt depth, and maintain the integrity of intestinal structure. Furthermore, Lic A altered cytokine levels and enhanced the body's antioxidant capacity. In conclusion, Lic A exbibits significant anti-Giardia effects both in vitro and in vivo, suggesting its potential as a promising antiparasitic drug candidate against giardiasis.
Keywords: Against giardiasis; Giardia duodenalis trophozoites; Licochalcone a.
Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Figures













Similar articles
-
Activity of Thioallyl Compounds From Garlic Against Giardia duodenalis Trophozoites and in Experimental Giardiasis.Front Cell Infect Microbiol. 2018 Oct 15;8:353. doi: 10.3389/fcimb.2018.00353. eCollection 2018. Front Cell Infect Microbiol. 2018. PMID: 30374433 Free PMC article.
-
Efficacy of Ageratum conyzoides extracts against Giardia duodenalis trophozoites: an experimental study.BMC Complement Med Ther. 2020 Feb 28;20(1):63. doi: 10.1186/s12906-020-2860-6. BMC Complement Med Ther. 2020. PMID: 32111225 Free PMC article.
-
Aminoguanidines: New leads for treatment of Giardia duodenalis infection.Int J Parasitol Drugs Drug Resist. 2019 Aug;10:38-44. doi: 10.1016/j.ijpddr.2019.04.003. Epub 2019 Apr 8. Int J Parasitol Drugs Drug Resist. 2019. PMID: 31015151 Free PMC article.
-
The proteasome of the differently-diverged eukaryote Giardia lamblia and its role in remodeling of the microtubule-based cytoskeleton.Crit Rev Microbiol. 2017 Aug;43(4):481-492. doi: 10.1080/1040841X.2016.1262814. Epub 2016 Dec 30. Crit Rev Microbiol. 2017. PMID: 28033730 Review.
-
Giardiasis in the post genomic era: treatment, drug resistance and novel therapeutic perspectives.Infect Disord Drug Targets. 2010 Aug;10(4):283-94. doi: 10.2174/187152610791591610. Infect Disord Drug Targets. 2010. PMID: 20429863 Review.
References
-
- Ansell B.R., McConville M.J., Ma'ayeh S.Y., Dagley M.J., Gasser R.B., Svärd S.G., Jex A.R. Drug resistance in Giardia duodenalis. Biotechnol. Adv. 2015;33:888–901. - PubMed
-
- Argüello-García R., Leitsch D., Skinner-Adams T., Ortega-Pierres M.G. Drug resistance in Giardia: mechanisms and alternative treatments for giardiasis. Adv. Parasitol. 2020;107:201–282. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical